Ignite Creation Date:
2024-05-05 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 9:53 AM
Study NCT ID:
NCT00734097
Status:
COMPLETED
Last Update Posted:
2012-10-10
First Post:
2008-08-11
Brief Title:
A Study of Nexium Esomeprazole 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease GORD After Treatment With a Full Dose of Proton Pump Inhibitor PPI
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An Open Label Multicentre Study of Nexium Esomeprazole 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease GORD After Treatment With a Full Dose of Proton Pump Inhibitor PPI
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NEON
Brief Summary:
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease heartburn who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NEON | None | None | None |